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A 22-amino-acid-long multibranched peptide construct (CLV) derived from the cleavage region (KIEPLGVAPTKAKRR*VVQREKR*)
of the human immunodeficiency virus (HIV) type-1 envelope precursor inhibits HIV infection (Virology, 1996, 223, 406–408). We
attempted to characterize its activity for Env expressed via a recombinant vaccinia virus (rVV): gp160 cleavage was delayed, but
not impaired, in the presence of CLV (10 mM), whereas neither Env production nor Env membrane expression was significantly
altered. Through the synthesis of analogs, we concluded that the presence of a cleavage sequence was required for inhibition of
syncytium formation by CLV in rVV-infected CD41 cell cultures: indeed, a single amino acid residue substitution (R*.S) in the
cleavage sites presented by CLV abolished its activity. Other analogs allowed us to further determine the region of CLV which
mediates its activity. The ability of a radiolabeled CLV analog to enter cells was also shown. Altogether, these data strongly suggest
that CLV acts on Env fusogenicity at least partially through interference with gp160 processing. © 1998 Academic Press
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INTRODUCTION
The surface glycoprotein gp120 and the transmem-
brane glycoprotein gp41 are cleavage products of the
gp160 precursor and the components of the mature hu-
man immunodeficiency virus (HIV) type-1 envelope (Env)
(Einfeld, 1996). gp120 and gp41 are non-covalently asso-
ciated at the virus surface, where they mediate HIV
binding to, and membrane fusion with, CD41 cells, re-
spectively (Moore et al., 1993; Einfeld, 1996).
The cleavage of gp160 into gp41 and gp120 is required
for activation of the HIV envelope fusion function: muta-
tion of gp160 cleavage sites impairs membrane fusion
through precursor cleavage inhibition (McCune et al.,
1988; Freed et al., 1989; Bosch and Pawlita, 1990). During
its biosynthetic pathway, gp160 cleavage results—likely
in a trans Golgi compartment (Pfeiffer et al., 1997)—from
the action of proteases that have not been unequivocally
identified: for some, furin activity is considered the can-
didate for Env cleavage but several works showed that
subtilisin-like protein convertases also fulfill the ex-
pected criteria (Hallenberger et al., 1992, 1997; Morikawa
et al., 1993; Onishi et al., 1994; Decroly et al., 1994, 1996,
1997; Gu et al., 1995; Inocencio et al., 1997; Einfeld, 1996).
Two potential conserved tryptic-like endoproteolytic
cleavage sites represented by clusters of basic amino
acid residues (aa) exist on gp160 (Bosch and Pawlita,
1990; Einfeld, 1996). A first site is defined by the se-
quence KAKRR (aa 505–509) and the other by the se-
quence REKR (aa 513–516). In vitro, furin cleaves more
efficiently the REKR site when compared to the KAKRR
sequence (Brakch et al., 1995). About 15% of mature
recombinant and viral Env is cleaved at site 1 and does
not organize in oligomers (Fenouillet and Gluckman,
1992) but it is clear that only the cleavage at site 2 leads
to fusogenic gp41 species (Freed et al., 1989; Bosch and
Pawlita, 1990): it is likely that the gp41 resulting from
cleavage at site 1 is not functional because the addi-
tional polar aa sequence alters gp41 fusion peptide prop-
erties. Surprisingly, it was shown that cleavage of Env
can occur when no dibasic sequence is present at the
cleavage site, which raises questions about the speci-
ficity of the protease that cleaves (Dubay et al., 1995).
Various linear peptides (Callebaut et al., 1996; De
Rossi et al., 1991; Neurath et al., 1992, 1995; Slepushkin
et al., 1993) and synthetic multibranched peptides (SPCs)
(Yahi et al., 1994; Benjouad et al., 1995; Barbouche et al.,
1998a) derived from HIV Env interfere with HIV infectivity
and syncytium formation in HIV-infected CD41 cell cul-
tures. The mode of action of these peptides remains
unclear but they are supposed to interfere either with
Env biosynthetic events or with post-CD4-binding events.
Recently, we also reported preliminary data showing that
a SPC (CLV; four branches of the KIEPLGVAPTKAKRRV-
VQREKR motif) derived from the sequence encompass-
ing the cleavage region of gp160 inhibits HIV infectivity
without cell toxicity (Sabatier et al., 1996). Based on this
observation and because it was described that peptidyl
chloromethylketones that possess the RXKR motif inter-
fere with gp160 cleavage and inhibit HIV infectivity (Hal-
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lenberger et al., 1992), we hypothesized that CLV may
alter the cell machinery involved in Env processing and
hence membrane fusion and HIV infectivity.
Here, we studied whether inhibition by CLV of syncy-
tium formation induced by Env depends on a reduced
Env production, on interference with gp160 processing,
or on an altered expression at the cell surface. Through
the synthesis of various CLV analogs, we determined the
region of CLV which was required for the inhibitory ac-
tivity. The ability of an active CLV analog to enter cells
was also studied.
RESULTS
The amount of Env production was not altered in the
presence of CLV
We previously reported (Sabatier et al., 1996) that a 10
mM concentration of CLV abolishes syncytium formation
mediated by rVV expressing HIV Env in CD41 cell cul-
tures. These conditions totally impair HIV infectivity,
whereas the control SPC C was inactive. Of note: (i) a 10
mM concentration of CLV did not display detectable cell
toxicity as assessed by proliferation assays (data not
shown and Sabatier et al., 1996), (ii) a 1 mM concentra-
tion of CLV inhibited by about 70% rVV-induced syncy-
tium formation, and (iii) a control rVV lacking HIV env
failed to induce syncytium formation (data not shown).
Because CLV may act through inhibition of Env pro-
duction, we examined by dot blot—to avoid any influ-
ence of Env conformation with the labeling procedure
(Fenouillet and Gluckman, 1991)—the production of Env
present in lysate (gp160, gp120, and gp41) and of se-
creted Env (gp120) 1 or 2 days postinfection. The pro-
duction was not modified by the presence of CLV (10 mM)
(the set of experiments with BHK-21 cells is shown in
Table 1; n 5 5 experiments; Env samples corresponding
to each condition were produced in three independent
cell cultures). The data obtained by ELISA were in agree-
ment with those obtained by dot blot assay: 2 days
postinfection, irrespective of the presence or the ab-
sence of CLV, coating with D7324 detected about 300 ng
of cell-associated gp120/106 cells and about 2 mg of
secreted gp120/106 cells and coating with D7323 de-
tected about 200 ng of cell-associated gp41/106 cells.
Membrane expression was normal in the
presence of CLV
One or 2 days postinfection with rVV, CEM cells pro-
ducing Env in the presence or in the absence of CLV (10
mM) were incubated with a pool of HIV1 sera to study the
kinetics of Env membrane expression (Fenouillet et al.,
1996, 1997): cells exhibited a similar level of Env at their
surface irrespective of the presence of CLV (Fig. 1). Ab
dilutions ranging from 1/50 to 1/50 000 led to similar data
(not shown). Surprisingly but reproducibly (n 5 3), the
presence of CLV slightly increased labeling.
CLV delayed the cleavage of the gp160 precursor
The gp160 cleavage into gp120 and gp41 in the presence
or in the absence of CLV (10 mM) was examined by pulse–
chase labeling. The amount of immunopurified labeled Env
was similar in all cases (Fig. 2A), in agreement with the data
obtained by dot blot and ELISA. According to Fenouillet and
Jones (1995) and Fenouillet et al. (1997), in the absence of
CLV, gp120 was detected after a 30-min chase, and mature
gp120—the increased MW of which reflects carbohydrate
maturation (Fenouillet and Jones, 1995)—was detected af-
ter a 2-h chase. Similar data were obtained when cells
were incubated with SPC C (not shown). Two hours post-
pulse, only a very faint band of gp160 was detected: it is
likely that most of the uncleaved gp160 species was sig-
nificantly degraded at that time and consequently was un-
detectable as a 160-kDa band after b-mercaptoethanol elu-
tion (as observed and discussed in Earl et al., 1991; Fenouil-
let and Jones, 1995). In the presence of CLV, gp160
appeared essentially uncleaved after a 30-min chase,
whereas a significant cleavage was detected 2 h postpulse.
FIG. 1. Effect of CLV on Env membrane expression. One or 2 days
postinfection with rVV9-1 in the presence (CLV) or in the absence (C) of
CLV, cells were incubated with a pool of HIV1 sera; staining of mem-
brane Env was performed with peroxidase-conjugated anti-human IgG.
TABLE 1
Quantitation of Env Expressed in the Presence (10 mM) of either a
Control SPC (C) or CLV by VV9-1-Infected BHK-21 Cells (ng/106 Cells)
1 or 2 Days Postinfection
Day11 Day12
C
Secreted Env 11006200 20006300
Cell-associated Env 2756 75 4006100
CLV
Secreted Env 13006300 20006700
Cell-associated Env 2756 75 3756 75
Note. Secreted Env: Env present in cell supernatants; cell-associated
Env: Env present in cell lysates; n 5 5 experiments.
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High-molecular-weight gp160 was still detected at this time.
The migration of the Env species as double bands has
been already observed (Fenouillet et al., 1997) in our dis-
criminating SDS–PAGE/pulse–chase analysis conditions.
To further examine the ability of Env to be processed in
the presence of CLV, a Western blot analysis of Env
stored either in cell supernatant or in cell lysate 2 days
postinfection was performed (Fig. 2B). The results sup-
ported the data presented in the pulse–chase study and
those obtained by dot blot and ELISA as reported above:
in the presence of CLV, a significant amount of cleaved
gp41 and gp120 was detected into the cell pellet; after
membrane expression, the gp120 subunit was efficiently
secreted into the cell supernatant.
Thus, cleavage of Env was delayed, but not inhibited,
in the presence of CLV.
CLV should present a functional cleavage
site to be active
To determine the aa involved in CLV activity, we syn-
thesized various analogs which were tested for their cell
toxicity and ability to inhibit syncytium formation induced
by rVV infection in CD41 cell cultures, as described in
Sabatier et al. (1996) (Table 2). Irrespective of their se-
quence and length, these analogs presented a cytotox-
icity similar to that of CLV. The L analog—which presents
a R509/516.S substitution in the cleavage sites—failed to
inhibit syncytium formation (Table 2). The fact that the S
analog—it presents a REKR motif without aa sequence
downstream this site—was inactive indicates that the
REKR sequence including the R516 residue adjacent to
the Lys core is not involved in CLV activity. In full con-
trast, the M analog—which contains a cleavage region
with aa upstream and downstream the cleavage site—
was as active as CLV, despite the deletion of a large part
of the sequence upstream the first cleavage site. The
ability of the various analogs to inhibit infection of C8166
cells by HIVMN was also examined: according to the data
presented above, the L and the S analogs were found
inactive (data not shown). These data indicate that CLV
exhibited its anti-HIV activity through the presence of a
functional cleavage sequence on the peptide construct.
CLV Y enters CEM cells
The ability of the active CLV Y analog to enter CEM
cells (Fig. 3) was studied. We observed that CLV Y was
able to rapidly bind cell membrane and enter cells (the
FIG. 2. Env cleavage in the presence of CLV. (A) Cells were pulse-
labeled for 30 min in the presence (1) or in the absence (2) of CLV (10
mM), 18 h postinfection with rVV9-1 in the presence (1) or in the
absence (2) of CLV, respectively. Cells were then chased for 30 or 120
min. After lysis of the cell pellet, Env was immunopurified using anti-HIV
human Abs and analyzed by SDS–PAGE (10%) and autofluorography.
MW is expressed in kDa. (B) Two days postinfection by rVV9-1 in the
presence (1) or in the absence (2) of CLV (10 mM), cells were lysed
(lysate: Lys) and their supernatant (Supt) was concentrated. Samples
were analyzed by SDS–PAGE (10% when the staining was performed
with either anti-gp41 or human anti-HIV Abs; 8% when the staining was
performed with anti-gp120 Abs). (o) gp160 species; (*) gp120 species;
() gp41 species).
TABLE 2
Cell Toxicity and Effect of Various SPCs Derived from the Cleavage Region of the HIV Env Precursor on
Syncytium Fomation Induced in CD41 Cell Cultures by rVV Expressing HIV Env (n 5 5 experiments)
Toxicity-free
concentration (M) Syncytium formation (IC90)
CLV: [KIEPLGVAPTKAKRRVVQREKR]4-K2-K-bA 3z10
25 1025
L: [KIEPLGVAPTKAKRSVVQREKS]4-K2-K-bA 3z10
25 None
M: [PTKAKRRVVQREKR]4-K2-K-bA 3z10
25 1025
S: [VVQREKR]4-K2-K-bA 3z10
25 None
C: [GPGKTL]8-K4-K2-K-bA 10
24 None
Note. [GPGKTL]8-K4-K2-K-bA is a negative SPC control; a reduction of the syncytium score by 90% (IC90) relative to the negative control was
considered to result from a significant inhibitory activity of the corresponding peptide.
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amount of internalized CLV Y was calculated as de-
scribed under Materials and Methods and in Barbouche
et al. (1998b) as ‘‘cell-associated radioactivity obtained
when incubation was performed in the absence of NaN3’’
minus ‘‘cell-associated radioactivity obtained when incu-
bation was performed in the presence of NaN3’’).
DISCUSSION
This work is the third to report the design and the
characterization of peptide compounds derived from the
endoproteolytic cleavage sequence of HIV Env. One of
these works showed that decanoylated peptides derived
from the gp160 cleavage region failed to inhibit in cell
culture gp160 cleavage. Moreover, their important cell
toxicity did not allow further development as anti-HIV
therapeutic agents (Decroly et al., 1994).
In strong contrast, the pioneer work by Hallenberger et
al. demonstrated that a set of peptide chloromethylk-
etones (PCMK) which are derived from the gp160 cleav-
age region ‘‘interfere with Env cleavage and hence its
activation’’ (Hallenberger et al., 1992). It is important to
note that, in this work, the authors showed that an im-
portant cleavage of Env does exist (about 50% when Env
was expressed by rVV in this study) in the presence of
PCMK and that despite the expression of an important
amount of cleaved Env, HIV infectivity is abolished.
We present here data which confirm and expand this
latter work. Indeed, we showed that a 10 mM concentra-
tion of CLV—a peptide which encompasses a large
sequence of the cleavage region of the Env precursor—
delayed, but did not prevent, gp160 processing, whereas
it fully abolished syncytium formation. This compound is
more potent than the PCMKs previously described (Hal-
lenberger et al., 1992). The ability of a labeled CLV analog
to enter cells is in agreement with such an intracellular
effect. However, this interference with gp160 cleavage
was not sufficient to alter substantially the amount of
cleaved Env produced and expressed at the cell surface.
The observed shedding into the cell supernatant of ma-
ture cleaved gp120 is another evidence that gp160 cleav-
age was not blocked by the treatment by CLV. Surpris-
ingly, the presence of CLV slightly increased Env mem-
brane expression, in agreement with the previous
observation of Hallenberger et al. (1992), who observed
that PCMKs slightly decrease shedding of gp120.
Because CLV altered at least the cleavage process
during biosynthesis, we hypothesized that the presence
of a cleavage substrate sequence on CLV was actually
responsible for its interference with membrane fusion. To
address this point, we synthesized various analogs of
CLV on the basis of the data obtained in a previous study
based on site-directed mutagenesis, which determined
the aa required for Env cleavage (Bosch and Pawlita,
1990; Einfeld, 1996). First, we synthesized a CLV analog
which presents a R . S substitution in the cleavage
sites. Such a mutation on env impairs Env cleavage
(Bosch and Pawlita, 1990). Such an analog was inactive.
Similarly, an analog which presents a REKR motif close
to the uncharged Lys core lacked activity (The Lys core
is uncharged as a result of the SPC synthesis). In full
contrast, the M analog which presents a functional site 1
was active, despite the removal of several aa upstream
to the functional cleavage site. From these data, we
conclude that the sole presence of a functional cleavage
region is responsible for CLV activity. This further argues
in favor of a CLV-induced inhibition of syncytium forma-
tion through interferences with the enzymatic machinery
involved in gp160 processing. Additional interferences of
CLV with some steps of the membrane fusion process
per se may act together with the interference with Env
cleavage to completely impair membrane fusion. It is
also possible that the presence of both cleaved and
uncleaved Env within the same oligomers late in the
intracellular routing or at the membrane disturbs the Env
functions and structure to inactivate it. These hypotheses
are under investigation to explain why CLV exhibits so
potent an effect on Env functions despite its apparently
slight effect on Env processing.
MATERIALS AND METHODS
Materials
D7324 (Aalto, Dublin, Ireland) is a polyclonal antibody
(Ab) against gp120 Ct (aa 502–516); D7323 is against
gp41 Ct (aa 845–860); 9305 and 9301 (DuPont de
Nemours, Dreieich, Germany) are mouse monoclonal
anti-gp120 Abs directed against aa 318–328 and aa 475–
486, respectively. Chemical products were of analytical
FIG. 3. Binding to, and internalization into, human CD41 lymphoid
cells of a labeled active CLV analog. CEM cells were incubated at 37°C
with the radiolabeled CLV Y analog. Cell-associated radioactivity when
incubation was performed in the presence of NaN3—a condition that
impairs endocytosis—was considered membrane-associated CLV Y
(Mb CLV). CLV Y present within the cells (Int CLV) was calculated as
follows: ‘‘cell-associated radioactivity obtained when incubation was
performed in the absence of NaN3 (Tot CLV)’’ minus ‘‘Mb CLV.’’
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grade (Sigma, St Louis, MO). Products for peptide syn-
thesis were from Perkin–Elmer (Paris, France).
Synthesis of synthetic polymeric constructions
Chemical synthesis of SPCs was performed by the
solid phase technique using Fmoc/t-butyl chemistry, as
described by Yahi et al. (1994). The crude peptides were
purified to homogeneity by C18 reversed-phase medium-
pressure liquid chromatography (Barbouche et al.,
1998a,b). The purity of the peptides was assessed by
analytical C18 reversed-phase high-pressure liquid chro-
matography (Barbouche et al., 1998a,b). Fractions con-
taining purified peptides were pooled and characterized
by both aa analysis after acid hydrolysis and mass spec-
trometry. They were then tested in bioassays. SPCs are
as follows: SPC C (a negative control): ([GPGKTL]8-K4-K2-
K-bA); SPC CLV: ([KIEPLGVAPTKAKRRVVQREKR]4-K2-K-
bA); SPC CLV L (long): ([KIEPLGVAPTKAKRSVVQREKS]4-
K2-K-bA); SPC CLV M (medium): ([PTKAKRRVVQREKR]4-
K2-K-bA); SPC CLV S (short): ([VVQREKR]4-K2-K-bA); and
SPC CLV Y (CLV analog used for radiolabeling): ([PTKAK-
RRVVQREKR]4-K2-K-Y).
Syncytium formation
Human lymphoid CD41 CEM cells—cultured in RPMI
1640 medium supplemented with 5% fetal calf serum
(FCS) and 1% Gln—were infected in 12-well plates in the
presence of various SPCs for 18 h with a recombinant
vaccinia virus (rVV) expressing HIVLai Env (Kie´ny et al.,
1988; VV9-1; 0.2 PFU/cell; a gift of Marie-Paule Kie`ny,
Transge`ne, Strasbourg, F), as described by Fenouillet et
al. (1993).
Env production and quantitation
Baby hamster kidney (BHK-21) cells—cultured in Glas-
gow medium supplemented with 5% FCS and 1%
Gln—or CEM cells were infected as described above.
Infections were performed in FCS-free medium to allow,
after 1 or 2 days, supernatant concentration [5-fold using
a 30-kDa cutoff Centriprep system (Amicon, Danvers,
MA)] (Fenouillet et al., 1993); cell pellets were lysed in
phosphate-buffered saline, pH 7.4 (PBS), 0.1% Triton
X100.
The quantities of Env obtained in the different systems
were determined by dot blot (described in Fenouillet and
Gluckman, 1991) and ELISA (Fenouillet et al., 1993), using
as reference a cell lysate spiked with a known amount of
recombinant Env (Fenouillet et al., 1992, 1993, 1996).
Briefly: (i) dot blot: 5, 2.5, and 1 ml of lysate (106 cells/10
mL of lysate) or 53 supernatant (106 cells/100 mL) ad-
justed to 10 ml final volume of PBS were blotted onto a
nitrocellulose filter. Staining was performed with a pool
of HIV1 sera (1:50) which was devoid of detectable Abs
against VV (Fenouillet et al., 1993) and preincubated with
CLV (3 z 1024 M) to inhibit a possible bias induced by the
reactivity of Abs with CLV present in the samples. Under
these conditions, the Abs used as described below re-
acted neither with uninfected cells incubated with 10 mM
CLV nor with the medium or cell lysate. Peroxidase-
labeled anti-human IgG Abs (Dakopatts, Glostrup, Den-
mark) were then added (1/100). (ii) ELISA: wells (Nunc,
Roskild, Denmark) were coated (200 ng/100 mL) with
D7324—to detect gp160 and gp120—or D7323—to de-
tect gp160 and gp41. Lysates or 53 supernatants were
added. After washing, the pool of HIV1 sera was added
and staining was performed as described above.
Alternatively, a Western blot analysis of Env present
either in cell supernatant or in cell lysate was performed
as reported by Fenouillet et al. (1996). Briefly, concen-
trated (53) supernatants (50 mL) and cell lysates (2 z 106
cells/50 mL) were submitted to SDS–polyacrylamide gel
electrophoresis (PAGE) under nonreducing conditions.
After blotting, staining was obtained (i) with human anti-
HIV-1 Abs (diluted 1/100 to detect Env species in the
supernatant), (ii) with a mixture of 9305 and 9301 mAbs
(diluted 1/50 to detect gp120 and gp160 in the lysates), or
(iii) with D7323 (diluted 1/100 to detect gp41 and gp160 in
the lysates). Incubations and washes were performed in
PBS 0.5% casein, 0.5% Tween 20. Peroxydase-conju-
gated anti-Abs were then incubated for 1 h before stain-
ing with diaminobenzidine.
Detection of Env membrane expression
Cells were infected with rVV for 1 or 2 days. After a
wash in PBS, cells were treated with 2% paraformalde-
hyde. After 18 h, 3 z 106 cells were washed in PBS 2%
casein (PBSC) and incubated for 2 h with a saturating
concentration (1:100) of the pool of HIV1 sera to detect
membrane Env as described (Fenouillet et al., 1996,
1997). After a wash, peroxidase-coupled anti-Abs were
added (1/50 in PBSC) for 1 h. After washes, chromogen
was added. The labeling was specific for the membrane
expression of Env, as it was dependent on the Ab con-
centration and as incubation with a pool of HIV2 sera did
not label infected cells (Fenouillet et al., 1997, and data
obtained under these conditions and not shown).
Env precursor cleavage
gp160 cleavage into gp120 and gp41 was examined by
pulse–chase labeling as described in Fenouillet et al.
(1995, 1997). Briefly, after starvation 15 h postinfection for
1 h, 107 cells were labeled for 30 mn with a [35S]Met/Cys
mixture (Amersham, UK; 300 mCi); Met-supplemented
(100 mg/mL) medium was then added for 30 or 120 min.
Cells were lysed in Tris 25 mM, 300 mM NaCl, pH 7.4,
0.5% Triton X-100, and 0.25% SDS and a pool of HIV1
sera (1:50) was added for 3 h in the same buffer. Protein
A–Sepharose (Pharmacia, Uppsala, Sweden) was then
added. After washes in the lysis buffer, elution was
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obtained with 10% SDS, 10% b-mercaptoethanol before
analysis by 10% SDS–PAGE (Fenouillet et al., 1997).
Internalization of an active radiolabeled CLV analog
The active CLV Y (5 mg) was labeled with 125I-labeled
Na (300 mCi) in a 4 nM iodogen-coated tube for 30 mn at
20°C (Barbouche et al., 1998a,b). Labeled CLV Y (sp act
50 mCi/mg) was purified on a PD10 column (Pharmacia).
CEM cells were incubated with 125I-labeled CLV Y in cell
culture medium for various times. Triplicates were per-
formed (n 5 2 experiments). For each incubation time, a
triplicate was similarly incubated but the presence of
0.1% NaN3 to avoid endocytosis as reported in Bar-
bouche et al. (1998b). Samples were then washed twice
with PBSC, 0.1% NaN3 and cell-associated radioactivity
was counted. Cell-associated radioactivity when incuba-
tion was performed in the presence of NaN3 represented
membrane-associated CLV Y. Accordingly, 125I-labeled
CLV Y present within the cells was calculated for each
time point as follows: ‘‘cell-associated radioactivity ob-
tained when incubation was performed in the absence of
NaN3’’ minus ‘‘cell-associated radioactivity obtained
when incubation was performed in the presence of
NaN3,’’ as reported by Barbouche et al. (1998b).
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